Meet Cromos Pharma at the 62nd ASH Annual Meeting & Exposition Cromos Pharma is delighted to be participating again this year at the 62nd ASH Annual Meeting & Exposition 5-8 December, 2020, the premier event for malignant and non-malignant hematology. Extensive expertise in hematology-oncology Cromos Pharma has extensive experience in managing all aspects of clinical trials in hematology-oncology in all Phases, I, II, III and post market/observational. Oncology studies represent
FDA Offers Guidance to Enhance Diversity in Clinical Trials The FDA released a statement (9 November 2020) outlining its commitment to promoting greater diversity in medical product development and issuing a new guidance document outlining the agency’s thinking on encouraging greater inclusivity. “Enhancing the Diversity of Clinical Trial Populations–Eligibility Criteria, Enrollment Practices, and Trial Designs.” The guidance provides recommendations for sponsors on how to
Cromos Pharma and Avance Clinical share details of innovative collaboration at BIO-Europe 2020 Avance Clinical and Cromos Pharma, with operations in Australia and Central/Eastern Europe, respectively, are successfully collaborating on a scalable clinical solution for biotechs. The collaboration allows biotechs to quickly start their pre-IND early phase studies in Australia, then expand to Central/Eastern Europe to access the large patient populations for their Phase 2 and 3 studies.
